Steven M Larson

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Advances in positron emission tomography applications for urologic cancers
    Steven M Larson
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Urol 18:65-70. 2008
  2. ncbi A pragmatic perspective on molecular targeted radionuclide therapy
    Steven M Larson
    Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:1S-3S. 2005
  3. ncbi Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer
    Steven M Larson
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:366-73. 2004
  4. ncbi Cancer drug development with the help of radiopharmaceuticals: academic experience
    Steven M Larson
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Pharm Des 15:950-6. 2009
  5. ncbi 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology
    Steven M Larson
    Memorial Sloan-Kettering Cancer Center New York, New York, USA
    J Nucl Med 47:901-3. 2006
  6. ncbi Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy
    Neeta Pandit-Taskar
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 49:1066-74. 2008
  7. ncbi Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis
    Tobias Leibold
    Department of Surgery Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:2783-9. 2011
  8. ncbi PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer
    Pat B Zanzonico
    Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:1966-71. 2004
  9. ncbi Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
    Richard J Robbins
    Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Endocrinol Metab 91:498-505. 2006
  10. ncbi Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Biother Radiopharm 20:534-46. 2005

Detail Information

Publications94

  1. ncbi Advances in positron emission tomography applications for urologic cancers
    Steven M Larson
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Urol 18:65-70. 2008
    ..This review introduces the concept of molecular imaging and summarizes current and future molecular imaging approaches that are likely to have a major impact on clinical practice in the near future...
  2. ncbi A pragmatic perspective on molecular targeted radionuclide therapy
    Steven M Larson
    Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:1S-3S. 2005
  3. ncbi Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer
    Steven M Larson
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:366-73. 2004
    ....
  4. ncbi Cancer drug development with the help of radiopharmaceuticals: academic experience
    Steven M Larson
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Pharm Des 15:950-6. 2009
    ....
  5. ncbi 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology
    Steven M Larson
    Memorial Sloan-Kettering Cancer Center New York, New York, USA
    J Nucl Med 47:901-3. 2006
  6. ncbi Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy
    Neeta Pandit-Taskar
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 49:1066-74. 2008
    ..An analysis was performed to assess lesion detectability by (111)In-J591 gamma-camera imaging compared with standard imaging methods and the effect of increasing antibody mass on lesion detectability, biodistribution, and dosimetry...
  7. ncbi Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis
    Tobias Leibold
    Department of Surgery Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:2783-9. 2011
    ..We prospectively evaluated tumor response with (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) early in the course of preoperative CRT...
  8. ncbi PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer
    Pat B Zanzonico
    Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:1966-71. 2004
    ..0151 cGy/MBq]) is recommended for (18)F-FDHT...
  9. ncbi Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
    Richard J Robbins
    Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Endocrinol Metab 91:498-505. 2006
    ..We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[(18)F]fluoro-2-deoxyglucose (FDG), would correlate with prognosis...
  10. ncbi Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Biother Radiopharm 20:534-46. 2005
    ..5 MBq (131)I-8H9 were significantly suppressed compared to controls. Radiolabeled 8H9 effectively targeted RMS xenografts and may have a potential clinical role in radioimmunotherapy...
  11. ncbi (124)I-huA33 antibody PET of colorectal cancer
    Jorge A Carrasquillo
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 52:1173-80. 2011
    ..We also determined the biodistribution of (124)I-huA33 when a large dose of human intravenous IgG (IVIG) was administered to manipulate the Fc receptor or when (124)I-huA33 was given via hepatic arterial infusion (HAI)...
  12. ncbi FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation
    Jeannine A Ruby
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Dis Colon Rectum 55:378-86. 2012
    ..At present there is no defined role for routine FDG-PET in the preoperative evaluation of nonmetastatic rectal cancer...
  13. ncbi (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo
    Mikhail Doubrovin
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 51:121-9. 2010
    ....
  14. ncbi Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003
    Peter M Smith-Jones
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA
    Nucl Med Biol 35:343-51. 2008
    ..The in vitro and in vivo behavior of the radiolabeled monoclonal antibody MORAb-003 was investigated as a prelude to a clinical trial...
  15. ncbi Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose
    Gregor J Förster
    Nuclear Medicine Research Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 47:140-9. 2006
    ..The objective of the current study, therefore, was to evaluate the reduction of kidney uptake of radiolabeled DOTA-biotin achieved by each of 4 different methods...
  16. ncbi 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 52:1878-85. 2011
    ..The primary aim of this analysis was to examine the quantitative features of antibody-antigen interactions in tumors and normal tissue after parenteral administration of antitumor antibodies to human patients...
  17. ncbi Deep-inspiration breath-hold PET/CT: clinical findings with a new technique for detection and characterization of thoracic lesions
    Gustavo S P Meirelles
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 48:712-9. 2007
    ..Our aim was to compare the detection and characterization of thoracic lesions on PET/CT with and without a deep-inspiration protocol...
  18. ncbi PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies
    Heiko Schoder
    Department of Radiology, Nuclear Medicine Service, and Gerschel PET Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:72S-81S. 2004
    ..This article summarizes preliminary data of PET/CT studies and highlights potential clinical applications for PET/CT, with particular emphasis on lymphoma, melanoma and gastrointestinal tumors...
  19. ncbi Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software
    George Sgouros
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 45:1366-72. 2004
    ..This input has typically been obtained from SPECT and planar imaging studies. The objective was to implement and evaluate PET-based, patient-specific, 3D dosimetry for thyroid cancer patients...
  20. ncbi 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions
    Amit Singnurkar
    Department of Radiology Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 51:1833-40. 2010
    ..The utility of (18)F-FDG PET/CT for response assessment in malignant lung tumors treated with radiofrequency ablation (RFA) and for the detection and prediction of local recurrence was investigated...
  21. ncbi Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma
    Sonal Bhandari
    Department of Pediatrics, New York Presbyterian Weill Cornell Medical College, New York, New York, USA
    Pediatr Blood Cancer 55:76-80. 2010
    ..To determine the prevalence of and risk factors for primary hypothyroidism following treatment with a radiolabeled monoclonal antibody ((131)I-3F8) in children with neuroblastoma...
  22. ncbi The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer
    Ravinder K Grewal
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 51:1361-7. 2010
    ..We performed planar imaging and SPECT/CT in a consecutive series of patients after (131)I therapy...
  23. ncbi Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Elizabeth R Dennis
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:519-24. 2012
    ..Prior studies have shown the prognostic value of a baseline BSI. This study tested whether treatment-related changes in BSI are prognostic for survival and compared BSI to prostate-specific antigen (PSA) as an outcome measure...
  24. ncbi Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, New York 10021, USA
    Clin Cancer Res 11:3210-6. 2005
    ..We tested the hypothesis that serial fluorodeoxyglucose positron emission tomography (FDG-PET) scans can serve as an outcome measure for patients with castrate metastatic prostate cancer treated with antimicrotubule chemotherapy...
  25. ncbi Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Endocrinol Metab 89:6010-6. 2004
    ..We conclude that the location and volume of metastases influence basal Tg, but not its responsiveness to rhTSH, whereas the histological type of carcinoma influences both basal Tg and responsiveness to rhTSH...
  26. ncbi Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET
    Peter M Smith-Jones
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:793-6. 2006
    ....
  27. ncbi Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer
    Gustavo S P Meirelles
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 16:6093-9. 2010
    ..To compare the diagnostic and prognostic value of [(18)F] fluorodeoxyglucose positron emission tomography (FDG-PET) and bone scans (BS) in the assessment of osseous lesions in patients with progressing prostate cancer...
  28. ncbi Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial
    Chaitanya R Divgi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 8:304-10. 2007
    ..We aimed to assess whether iodine-124-labelled antibody chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressive renal tumour...
  29. ncbi Evaluation of different methods of 18F-FDG-PET target volume delineation in the radiotherapy of head and neck cancer
    Carlo Greco
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Clin Oncol 31:439-45. 2008
    ..To quantify differences between the alternative methods of F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)-based delineation of the gross tumor volume in patients with head and neck cancer...
  30. ncbi Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 429, New York, NY 10065, USA
    J Neurooncol 97:409-18. 2010
    ..The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies. It has the potential to increase survival with better than expected quality of life...
  31. ncbi Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5465-70. 2007
    ..We tested the toxicity, pharmacokinetics, and dosimetry of intraventricular iodine-131-labeled monoclonal antibody 3F8 (131I-3F8) targeting GD2-positive CNS/LM disease in a phase I clinical trial...
  32. ncbi Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma
    Michael Rivera
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 113:48-56. 2008
    ..However, to the authors' knowledge, the histology of FDG-PET-positive RAIR metastatic thyroid carcinoma has not been described to date...
  33. ncbi 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo
    Jason P Holland
    Radiochemistry Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 51:1293-300. 2010
    ....
  34. ncbi [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity
    Pat Zanzonico
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Eur J Nucl Med Mol Imaging 33:988-97. 2006
    ....
  35. ncbi Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Todd L Rosenblat
    Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5303-11. 2010
    ..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy...
  36. ncbi Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET
    Bradley J Beattie
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 51:183-92. 2010
    ....
  37. ncbi Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients
    Daniel A Pryma
    Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 47:1260-6. 2006
    ..However, there is limited information with regard to the true diagnostic accuracy and prognostic value of 18F-FDG PET in this disease...
  38. ncbi Positron emission tomography predicts survival in malignant pleural mesothelioma
    Raja M Flores
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Thorac Cardiovasc Surg 132:763-8. 2006
    ..Because mediastinal nodal metastasis is known to be associated with poor prognosis, we hypothesized that standard uptake value on fluorodeoxyglucose positron emission tomography might independently predict survival...
  39. ncbi Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software
    Katherine S Kolbert
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:143-9. 2007
    ..The objective of this work was to determine normal organ (131)I dosimetry in patients undergoing radioiodide therapy for thyroid cancer by use of serial scanning with (124)I PET...
  40. ncbi Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase
    Elmer B Santos
    Department of Radiology, Memorial Sloan Kettering Cancer Center MSKCC, 1275 York Avenue, New York, New York 10021, USA
    Nat Med 15:338-44. 2009
    ..This sensitive imaging technology has application to many in vivo cell-based studies in a wide array of mouse models...
  41. ncbi Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer
    Seng Chuan Ong
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 49:532-40. 2008
    ..We investigated the clinical utility of 18F-FDG PET/CT in this setting...
  42. ncbi In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene
    Mikhail M Doubrovin
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 67:11959-69. 2007
    ..The hNET-based system described may thus have significant potential as a nonimmunogenic reporter for extended repeated quantitative in vivo imaging of transduced cells in man...
  43. ncbi Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation
    Caio S R Nahas
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 15:704-11. 2008
    ....
  44. ncbi 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:4761-9. 2005
    ..We calculated sensitivity and specificity of PET and correlated PET findings with PSA values, other clinical parameters, and conventional imaging, when available...
  45. ncbi Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 45:559-66. 2004
    ..Previous studies suggested that measurements of (18)F-FDG accumulation in tissue might be affected by the image reconstruction method, but the clinical relevance of these findings has not been assessed...
  46. ncbi Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal
    R Michael Tuttle
    Division of Endocrinology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 49:764-70. 2008
    ..However, no published study has determined the effectiveness of rhTSH preparations on the important endpoint of disease recurrence...
  47. ncbi Clearance kinetics and external dosimetry of 131I-labeled murine and humanized monoclonal antibody A33 in patients with colon cancer: radiation safety implications
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Health Phys 96:550-7. 2009
    ..As other monoclonal antibodies progress from murine to humanized forms, radiopharmacokinetics should be evaluated for clinical and radiation safety implications...
  48. ncbi Feasibility of ex vivo FDG PET of the colon
    Marc J Gollub
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10023, USA
    Radiology 252:232-9. 2009
    ....
  49. ncbi The CT motion quantitation of lung lesions and its impact on PET-measured SUVs
    Yusuf E Erdi
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:1287-92. 2004
    ..Therefore, an incongruent lesion position during CT acquisition will bias activity estimates using PET. In this study, we systematically analyzed the range of activity concentration changes, hence SUV, for lung lesions...
  50. ncbi Measurement of lung tumor motion using respiration-correlated CT
    Gig S Mageras
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 60:933-41. 2004
    ..We investigate the characteristics of lung tumor motion measured with respiration-correlated computed tomography (RCCT) and examine the method's applicability to radiotherapy planning and treatment...
  51. ncbi Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma
    Raja M Flores
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Thorac Cardiovasc Surg 126:11-6. 2003
    ..Small studies suggest that fluorodeoxyglucose-positron emission tomography may improve staging. We analyzed our experience to determine more definitively the potential utility of fluorodeoxyglucose-positron emission tomography...
  52. ncbi Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance
    Helmut Schoellnast
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cardiovasc Intervent Radiol 34:S182-5. 2011
    ..Therefore, before RFA, FDG PET can guide initial needle placement, but it does not serve as a monitoring tool to evaluate residual viable tissue during the procedure...
  53. ncbi Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion
    Heiko Schoder
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, Box 77, 1275 York Ave, New York, NY 10021, USA
    Radiology 231:65-72. 2004
    ..To compare diagnostic accuracy of attenuation-corrected positron emission tomography (PET) with fused PET and computed tomography (CT) in patients with head and neck cancer and to evaluate the effect of PET/CT findings on patient care...
  54. ncbi Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels
    Seng C Ong
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:501-7. 2007
    ..The role of (18)F-FDG PET in MTC remains somewhat unclear. We reviewed our own experience with (18)F-FDG PET in postthyroidectomy MTC patients with elevated calcitonin...
  55. ncbi Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases
    Timothy Akhurst
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:8713-6. 2005
    ..CONCLUSION: These results indicate that FDG-PET scanning should be interpreted in the context of concurrent cytotoxic therapy. FDG-PET scanning results may also be useful in assessment of response to such cytotoxic therapies...
  56. ncbi Deep-inspiration breath-hold PET/CT of the thorax
    Sadek A Nehmeh
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:22-6. 2007
    ..This article presents particular emphasis on the technical aspects required for clinical implementation...
  57. ncbi Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid
    Ping He
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA corrected
    Eur J Nucl Med Mol Imaging 38:334-42. 2011
    ..We now describe a two-compartment model to account for the ventricular reservoir of (131)I-3F8 and to identify limiting factors that may impact therapeutic ratio...
  58. ncbi Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
    Michael J Evans
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 108:9578-82. 2011
    ....
  59. ncbi 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI
    Heiko Schoder
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:755-62. 2006
    ..In particular, the value of combined PET/CT has not been determined in this group of patients...
  60. ncbi Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes
    Guenther Koehne
    Allogeneic Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Nat Biotechnol 21:405-13. 2003
    ..This technique for imaging the migration of ex vivo-transduced antigen-specific T cells in vivo is informative, nontoxic, and potentially applicable to humans...
  61. ncbi Positron emission tomography for prostate, bladder, and renal cancer
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Nucl Med 34:274-92. 2004
    ..Bladder cancer imaging with 11C choline, 11C methionine, or 11C- acetate deserves further study...
  62. ncbi Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI
    Stig Palm
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 44:1148-55. 2003
    ..MicroPET and MRI-based preclinical biodistribution and localization data were obtained and used to assess the therapeutic potential of (90)Y-trastuzumab monoclonal antibody (mAb) (anti-HER2/neu) against ovarian carcinoma...
  63. ncbi Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer
    Michael J Morris
    Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Urology 59:913-8. 2002
    ..Post-treatment changes in the SUV tend to correlate with changes in PSA...
  64. ncbi Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer
    Steven M Larson
    Department of Radiology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer J 10:243-50. 2004
    ..The addition of CT to the PET imaging, causes a significant reduction in uncertainty of image interpretation and improves the distinction between benign and malignant causes for FDG-PET positive sites...
  65. ncbi Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT
    Josef J Fox
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 52:1727-32. 2011
    ..We propose a standardized approach to quantitative molecular imaging (MI) in cancer patients with multiple lesions...
  66. ncbi Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
    Heiko Schoder
    Memorial Sloan Kettering Cancer Center, Department of Radiology, Nuclear Medicine Service, Box 77, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:4643-51. 2005
    ..18)Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma. We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease...
  67. ncbi Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system
    Oula Penate Medina
    Molecular Pharmacology and Chemistry Department, Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue 10021 New York, New York, United States
    J Control Release 149:292-8. 2011
    ..SKI 243 and liposomal SKI 243 are both taken up by tumor xenografts but liposomal SKI 243 remained in the blood longer and consequently exhibited a 3- to 6-fold increase in uptake in the tumor among several other organs...
  68. ncbi Targeted elimination of prostate cancer by genetically directed human T lymphocytes
    Terence P F Gade
    Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 65:9080-8. 2005
    ..These results thus provide a strong rationale for undertaking phase I clinical studies to assess PSMA-targeted T cells in patients with metastatic prostate cancer...
  69. ncbi Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET)
    Yusuf E Erdi
    Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Radiother Oncol 62:51-60. 2002
    ..Thus, the PET data reduces the likelihood of geographic misses and hopefully improves the chance of achieving local control...
  70. ncbi Peritoneal carcinomatosis: role of (18)F-FDG PET
    Alla Turlakow
    Department of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 44:1407-12. 2003
    ....
  71. ncbi Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer
    Rodolfo Nunez
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 43:46-55. 2002
    ..Our aim was to detect the proportion of bone and soft-tissue lesions that represent metabolically active tumor sites in patients with progressive metastatic prostate cancer...
  72. ncbi PET/CT in non-small-cell lung cancer: value of respiratory-gated PET
    Steven M Larson
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Chang Gung Med J 28:306-14. 2005
    ..We have successfully taken the first step in an attempt to correct for respiratory motion artifacts in PET imaging of lung lesions. (Chang..
  73. ncbi Positron emission tomography in thyroid cancer management
    Steven M Larson
    Department of Radiology, Nuclear Medicine Service, Laurent and Alberta Gershel PET Center, New York, NY, USA
    Semin Roentgenol 37:169-74. 2002
    ..PET may also be useful for lesion specific dosimetry, with I-124. The combination of PET and CT in the same gantry facilitates localization of thyroid cancer PET scan abnormalities in relationship to critical organs and structures...
  74. ncbi Dependence of FDG uptake on tumor microenvironment
    Andrei Pugachev
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 62:545-53. 2005
    ..To investigate the factors affecting the (18)F-fluorodeoxyglucose ((18)F-FDG) uptake in tumors at a microscopic level, by correlating it with tumor hypoxia, cellular proliferation, and blood perfusion...
  75. ncbi Combined CT colonography and 18F-FDG PET of colon polyps: potential technique for selective detection of cancer and precancerous lesions
    Marc J Gollub
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Rm C276F, New York, NY 10021, USA
    AJR Am J Roentgenol 188:130-8. 2007
    ..The purpose of this study was to determine the feasibility of imaging the colon with fused CT colonography (CTC) and 18F-FDG PET and to correlate the findings with the histologic features of polyps...
  76. ncbi Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial
    Robert J Downey
    Thoracic Service and Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:428-32. 2003
    ....
  77. ncbi A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 43:1482-8. 2002
    ..During this same time period, other patients at our center were prepared for RRA by hormone withdrawal...
  78. ncbi Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
    ..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans...
  79. ncbi CT in PET/CT: essential features of interpretation
    Heiko Schoder
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:1249-51. 2005
  80. ncbi An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer
    Tim Akhurst
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Thorac Surg 73:259-64; discussion 264-6. 2002
    ..Aside from one 9-patient study, there are no data comparing FDG-PET imaging with surgical staging of NSCLC after induction therapy...
  81. ncbi Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors
    Darren R Veach
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Nucl Med Biol 32:313-21. 2005
    ..8-fold uptake selectivity for the Bcr-Abl-expressing K562 cells at 60 min. These results suggest that pyridopyrimidinone radiotracers may be useful in imaging Abl-, Bcr-Abl- or Src-expressing malignancies...
  82. ncbi Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
    Jason A Konner
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5288-95. 2010
    ..This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD)...
  83. ncbi Association of vascular 18F-FDG uptake with vascular calcification
    Mark P S Dunphy
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 46:1278-84. 2005
    ..This investigation examines the geographic relationship of focal vascular (18)F-FDG uptake, as a marker of atherosclerotic inflammation, to arterial calcification detected by contemporaneous CT...
  84. ncbi What nuclear cardiology can learn from nuclear oncology
    Ismet Sarikaya
    Section of Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Cardiol 10:324-8. 2003
  85. ncbi A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes
    Vivian E Strong
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Surg Endosc 22:386-91. 2008
    ..These PET probes are handheld, allowing for real-time evaluation of cancer using a tool that provides surgeons with better intraoperative assessment of tumor sites...
  86. ncbi Respiratory artefact causing malpositioning of liver dome lesion in right lower lung
    Ismet Sarikaya
    Memorial Sloan Kettering Cancer Center, Nuclear Medicine Section, New York, NY 10021, USA
    Clin Nucl Med 28:943-4. 2003
    ..To overcome this respiration artefact the authors suggest a routine review of the nonattenuation-corrected PET images, particularly when evaluating liver dome and lower lung lesions...
  87. ncbi Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET
    Neeta Pandit-Taskar
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    AJR Am J Roentgenol 183:1143-7. 2004
    ..7%) were malignant. Therefore, although rare, unexplained focal abdominal FDG uptake should not be ignored and further diagnostic workup is warranted...
  88. ncbi Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas
    Michelle S Bradbury
    Department of Radiology, Sloan Kettering Institute for Cancer Research, New York, New York 10021, USA
    J Nucl Med 49:422-9. 2008
    ..Our goal was to develop a robust and reproducible method of kinetic analysis for the quantitative evaluation of tumor proliferation...
  89. ncbi 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice
    Gobalakrishnan Sundaresan
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    J Nucl Med 44:1962-9. 2003
    ..CONCLUSION: (124)I labeling of engineered antibody fragments provides a promising new class of tumor-specific probes for PET imaging of tumors and metastases...
  90. ncbi JNM supplement on molecular radiotherapy
    C Oliver Wong
    J Nucl Med 46:1765-6; author reply 1766. 2005
  91. ncbi New strategies in radioimmunotherapy for lymphoma
    Neeta Pandit-Taskar
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 5:364-71. 2003
    ..This review highlights features of radioimmunotherapy that are relevant to non-Hodgkin's lymphoma, focusing on the two anti-CD20 antibodies...
  92. ncbi Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide
    William J McBride
    Immunomedics, Inc, Morris Plains, New Jersey, USA
    J Nucl Med 47:1678-88. 2006
    ....
  93. ncbi A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology, Austin, and Repatriation Medical Centre, 3084 Australia
    Clin Cancer Res 9:1639-47. 2003
    ....
  94. ncbi NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer
    Donald A Podoloff
    J Natl Compr Canc Netw 5:S1-S22; quiz S23-2. 2007
    ..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...